Mounjaro side effects: Common and uncommon effects you should know

04 Apr

Mounjaro (tirzepatide) belongs to a new generation of drugs against type 2 diabetes and obesity, and interest has increased sharply since it was approved in Europe. With the increased interest also come more questions about side effects — what is normal, what requires medical attention and how Mounjaro differs from, say, Ozempic in this regard. This article reviews what we know about tirzepatide side effects based on clinical studies and practical experience, without glossing over what is actually troublesome.

Mounjaro stomach problems and nausea — the most common thing people experience

The vast majority of side effects with Mounjaro are linked to the gastrointestinal tract. In clinical trials (SURPASS program, data from 2021–2022), up to 44% of participants reported nausea, and the proportion was highest in the first weeks after dose escalation. Mounjaro’s nausea occurs primarily because tirzepatide slows the rate of gastric emptying — an effect known as delayed gastric emptying — which means food stays in the stomach longer.

In addition to nausea, diarrhoea, vomiting, constipation and belching are among the most common symptoms. Mounjaro stomach problems tend to be dose-related: they occur more often when titrating to 10 mg and 15 mg than at the starting dose of 2.5 mg. The practical advice from most treating doctors is to eat more slowly, avoid fatty and strongly spiced foods, keep portions small and give the body at least four weeks to adjust to each new dose level.

How long do the gastrointestinal problems last?

In clinical data, it can be seen that most people’s stomach problems subside after four to twelve weeks on a stable dose. However, it is not unusual for the nausea to return briefly each time the dose is increased. Approximately 5–6% of participants in the SURPASS trials discontinued treatment due to gastrointestinal adverse events—which is slightly higher than for semaglutide (Ozempic) at comparable weight loss doses.

A practical experience from endocrinology clinics is that the timing of the injection matters. Many patients report that they feel best injecting in the evening so that the possible three to six hours of nausea occur during the night, not in the middle of the work day.

Mounjaro side effects sleep and fatigue

Sleep problems are not among the side effects highlighted most in the product information, but mounjaro side effects sleep is a topic that recurs in patient forums and in clinical follow-up. There are a couple of mechanisms that are discussed.

GLP-1 receptor agonists — and Mounjaro also acts on the GIP receptor — affect appetite regulation and energy metabolism in a way that can alter the sleep cycle, at least temporarily. In addition, many patients experience vivid dreams or fragmented sleep during the first weeks, especially in connection with dose increases. Whether this is a direct pharmacological effect or a consequence of the altered caloric balance (rapid weight loss can itself affect the sleep architecture) is not completely clear in the literature.

Fatigue and general lethargy are reported by approximately 10-12% of patients in the studies. It is important to distinguish between fatigue associated with reduced calorie intake — the body is going through an adaptation phase — and a more prolonged exhaustion that may indicate that the body’s electrolyte or nutritional status has been affected. In the case of fatigue that lasts longer than a few weeks, or in the case of dizziness that occurs when standing up, you should contact your doctor to rule out dehydration or deficiency conditions.

Sleep problems — when to act?

Most sleep disturbances associated with Mounjaro are transient and resolve spontaneously within four to eight weeks. If the sleep problems are severe or affect the ability to work, it is worth discussing the timing of injections with their doctor — some patients feel better by switching from evening to morning injections. Sleep disturbances that persist in combination with palpitations, profuse sweating or severe fatigue should always be investigated as they may indicate an underlying condition not directly linked to the drug.

Uncommon but serious side effects of tirzepatide

In addition to the usual gastrointestinal complaints, there are a number of unusual side effects that are important to be aware of — not because they are likely, but because they require prompt assessment if they occur.

Pancreatitis is the most serious gastrointestinal risk. In clinical trials, acute pancreatitis was reported in 0.2-0.3% of patients using tirsepatide. The symptoms are severe pain in the upper part of the abdomen that can radiate to the back, nausea and fever. In the event of these symptoms, treatment must be stopped immediately and emergency care sought. Mounjaro should not be used in patients with a previous history of pancreatitis without careful medical judgment.

Gallbladder problems, including gallstones and inflammation of the gallbladder (cholecystitis), are a well-known complication of rapid weight loss in general — and also occur during Mounjaro treatment. The risk increases with weight loss faster than 1–1.5 kg per week over a longer period.

• Kidney effects in case of dehydration: repeated vomiting or diarrhea can lead to dehydration, which in turn puts a strain on the kidneys, especially in elderly patients

• Hypoglycaemia: the risk is low with monotherapy but increases significantly if Mounjaro is combined with insulin or sulphonylureas

• Heart rate increase: a slight increase in resting heart rate (5-15 beats per minute) has been observed, comparable to that seen with semaglutide

• Injection reactions: redness, swelling or itching at the injection site occur in 5-7% and are usually mild and short-lived

• Alopecia (hair loss): reported by some patients, probably as a result of rapid weight loss rather than a direct drug effect

Thyroid cancer is mentioned in the safety information based on animal data (rat models), but there is no confirmed increased risk in humans yet. However, Mounjaro should not be used by patients with multiple endocrine neoplasia type 2 (MEN2) or known medullary thyroid cancer in the family.

Mounjaro compared to Ozempic — similar but not identical side effects

Since both Mounjaro and Ozempic (semaglutide) belong to incretin-based treatments and are current for similar patient groups, the comparison is natural. Tirzepatid side effects and semaglutide side effects largely overlap, but there are meaningful differences.

Mounjaro activates both GIP and GLP-1 receptors, while Ozempic activates GLP-1 alone. The dual receptor activation generally produces stronger weight loss but also appears to be linked to a slightly higher frequency of gastrointestinal side effects, at least at high doses. In head-to-head analysis (SURPASS-CVOT and data published in 2023), nausea and diarrhea were numerically more common with tirzepatide 15 mg than with semaglutide 1 mg, but the differences were not dramatic.

|Side effect|Mounjaro (tirzepatid)|Ozempic (semaglutide)|

|Nausea| 40–44 % | 30–40 % |

|Diarrhea| 20–25 % | 15–20 % |

|Vomiting| 15–20 % | 10–15 % |

|Constipation| 15–20 % | 10–15 % |

|Heart rate increase|5–15 beats/min|5–10 beats/min|

|Pancreatitis| ~0,2–0,3 % | ~0,1–0,2 % |

One difference patients sometimes report is that mounjaro side effects tend to be a little more intense in the first few days after a dose increase but subside more quickly than with Ozempic. It is a clinical observation rather than a statistically robust conclusion, but it recurs often enough to be worth mentioning.

Ozempic has been available for a long time and has a longer side effect record in a real clinical setting. Mounjaro is newer to the European market, and long-term data (>5 years) is still limited. It is not a reason to avoid treatment, but it is a reason to be extra careful with follow-up and to report unusual symptoms to your doctor.

How to deal with side effects practically and when to contact a doctor

Knowing whether a side effect is expected and transient or a warning sign that requires action is one of the most practical questions for anyone starting Mounjaro treatment. Side effects mounjaro should always be discussed with the prescribing doctor or pharmacist, but there are some rules of thumb worth knowing.

Nausea, mild diarrhea and fatigue in the first few weeks are expected and do not require emergency contact — they should be managed with lifestyle adjustments and patience. However, you should seek emergency care or contact a doctor immediately in the event of:

• Severe abdominal pain, especially in the upper part of the abdomen, with or without fever (suspected pancreatitis)

• Signs of severe dehydration: severe dizziness, very dark urine, inability to retain fluids

• Symptoms of low blood sugar if you take insulin at the same time: tremors, profuse sweating, confusion

• Swelling of the throat, difficulty breathing or severe skin reaction (anaphylaxis, rare but serious)

• Persistent palpitations or chest pain

Dose adjustments are an important tool. If the side effects are intolerable, there is the option of staying on a lower dose for a longer time — for example, staying on 5 mg for eight weeks instead of four — before going up. It is a medical decision to be made with the doctor, but it is an option that clinical guidelines support.

Nutritional status is worth actively monitoring. Rapid weight loss increases the risk of a lack of fat-soluble vitamins, zinc and B12. A simple annual blood count is usually sufficient, but symptoms such as hair loss, numbness in the hands or extreme fatigue may warrant a more rapid check.

The experience of patients who successfully up-titrate without discontinuing treatment is relatively uniform: most side effects are worst in the first two to three weeks of a new dose and improve markedly thereafter. Having a realistic expectation scenario — that it may feel hard, but that it will likely pass — in itself seems to help patients stay in treatment long enough to see results.

.entry-content